{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1563"},{"groupId":"OG001","value":"0.3143"},{"groupId":"OG002","value":"0.5429"},{"groupId":"OG003","value":"0.6667"},{"groupId":"OG004","value":"0.750"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"24"}],"units":"Participants"}],"description":"A confirmed response is defined as stringent complete response, complete response (CR), very good partial response, or partial response (PR) noted as the objective status on 2 separate evaluations while receiving ixazomib citrate with or without dexamethasone. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. 95% confidence intervals for the true success proportion will be calculated by the exact binomial method.","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Ixazomib Citrate and Dexamethasone)"},{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (Ixazomib Citrate and Dexamethasone)"},{"description":"Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Arm C (Higher-dose Ixazomib Citrate and Dexamethasone)"},{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Arm D (Ixazomib Citrate, Dexamethasone, and Cyclophosphamide)"},{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Arm E (Ixazomib Citrate, Cyclophosphamide, Daratumumab)"}],"paramType":"NUMBER","populationDescription":"All eligible patients that received treatment and a disease evaluation.","reportingStatus":"POSTED","timeFrame":"2.5 years","title":"Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and Cyclophosphamide (Arm D), or With Dexamethasone, Cyclophosphamide, Daratumumab (Arm E)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}